CytomX Therapeutics CTMX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -181.9%-206pp | -29.4%-47.4pp | 20.5%+15.2pp | 30.6%+25.8pp | 24.4%+15.3pp | |
| Net margin | -166.4%— | -22.8%— | 24.7%— | —— | —— | |
| EBITDA margin | -181.5%-206pp | -29.2%-47.4pp | 20.6%+15.2pp | 30.7%+25.8pp | 24.5%+15.3pp | |
| Free cash flow margin | -225.6%-170pp | -99.5%-36.8pp | -63.7%+6.4pp | -55.1%+17.1pp | -55.3%+22.2pp | |
| Returns | ||||||
| Return on assets | -25.8%— | -12.8%— | 18.9%— | —— | —— | |
| Efficiency | ||||||
| Asset turnover | 0.2×-0.9× | 0.6×-0.3× | 0.8×+0.1× | 0.8×+0.2× | 1×+0.5× | |
| Liquidity | ||||||
| Current ratio | 10.4×+8.7× | 3.1×+1.8× | 3.6×+2.6× | 4.2×+3.2× | 1.7×+0.6× | |
| Quick ratio | 10.4×+8.7× | 3.1×+1.8× | 3.6×+2.6× | 4.2×+3.2× | 1.7×+0.6× | |
| Cash ratio | 0.8×-0.1× | 0.3×-0.2× | 0.8×+0.5× | 1.3×+0.9× | 0.9×+0.7× | |
| Leverage | ||||||
| Debt-to-equity | 0×— | 0×— | —— | —— | —— | |
| Debt-to-assets | 0×-0.1× | 0×0.0× | 0×0.0× | 0×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $1.80+528% | $0.72+13,393% | $0.65+336% | $0.93+353% | $0.29+175% | |
| Valuation | ||||||
| Market capitalization | $711.89M+94.8% | $721.79M+795% | $526.07M+471% | $337.14M+255% | $50.93M-65.5% | |
| Enterprise value | $685.92M+110% | $713.37M+1,273% | $497.48M+700% | $294.99M+364% | $11.47M-90.8% | |
| Price / sales | 20×+17.6× | 9.5×+8.9× | 4.6×+3.9× | 2.4×+1.6× | 0.3×-0.9× | |
| Price / book | 2.2×-12.4× | 7.3×— | —— | —— | —— | |
| EV / sales | 19.3×+17.1× | 9.4×+9.0× | 4.4×+3.9× | 2.1×+1.6× | 0.1×-1.0× | |
| Free cash flow yield | -11.3%+11.0pp | -10.5%+96.9pp | -13.8%+82.6pp | -23%+67.7pp | -160.1%-97.6pp | |
| Earnings yield | -8.3%-19.7pp | -2.4%— | 5.3%— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do CytomX Therapeutics's ratios come from?
- Every ratio is computed from CytomX Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
